Aptose Biosciences Merger Agreement With HS North America

Aptose Biosciences Inc. has entered into an amended and restated arrangement agreement dated February 23, 2026 with HS North America Ltd. as the purchaser and Hanmi Pharmaceutical Co. Ltd. as the parent.

The filing includes provisions covering the arrangement mechanics, interim and final court orders, shareholder meetings and circulars, and treatment of incentive securities and warrants. It also addresses regulatory approvals, TSX delisting, transaction litigation, and support and voting agreements, including non-solicitation and right-to-match style terms.